Anterix

Anterix Inc earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 3% discount to our quantitative fair value estimate of $86.33 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's solid growth increases our valuation estimate. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 5-year growth of 60.8% falls in the top 10% compared with peers globally. Relatively strong trailing five-year revenue growth suggests a compelling trajectory for future sales and earnings, which contributes to our view that shares are cheap.

Alternatively, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield, a core component of profitability, lies in the bottom 1% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.